Table 2 The distribution of NOS3, EDN1 and EDNRA genotypes according to the presence and severity of retinopathy of prematurity (ROP).

From: Association of endothelial nitric oxide synthase (NOS3) rs2070744 variant with advanced retinopathy of prematurity: a case–control study and meta-analysis

Genotype

Incidence and outcome of ROP

Statistical Analysis

I + II vs. III

OR (95%CI); P

I

No ROP

N = 105

II

ROP not requiring treatment; N = 90

III

ROP requiring treatment; N = 90

NOS3 rs2070744 T > C

TT

43 (41.0)

31 (34.4)

41 (45.6)

Studied effect:

Dom. 0.73 (0.44–1.2), 0.224

Rec. 0.34 (0.15 − 0.79), 0.009a

Allele freq. 0.65 (0.45–0.95), 0.023

TC

43 (41.0)

39 (43.3)

42 (46.7)

CC

19 (18.0)

20 (22.3)

7 (7.7)

MAF; PHWE

0.386; 0.614

0.439; 0.561

0.311; 0.689

NOS3 rs1799983 G > T (Glu298Asp)

GG

54 (52.0)

51 (56.7)

48 (53.3)

Studied effect:

Dom. 1.0 (0.63–1.7), 0.901

Rec. 1.4 (0.59–3.4), 0.424

Allele freq. 1.1 (0.77–1.6), 0.656

GT

42 (40.4)

33 (36.7)

33 (36.7)

TT

8 (7.6)

6 (6.6)

9 (10.0)

MAF; PHWE

0.279; 0.721

0.250; 0.750

0.283; 0.717

NOS3 rs2070744/rs1799983

TT + TC/GG + GT

83 (79.8)

67 (74.4)

77 (85.6)

1.0 (Reference)

0.26 (0.09–0.76), 0.009b

1.95 (0.61–6.2), 0.254

0.73 (0.19–2.8), 0.649

CC/GG + GT

13 (12.5)

17 (18.9)

4 (4.4)

TT + TC/TT

3 (2.9)

3 (3.3)

6 (6.7)

CC/TT

5 (4.8)

3 (3.3)

3 (3.3)

EDN1 rs5370 G > T

GG

70 (66.7)

59 (65.6)

55 (62.5)

Studied effect:

Dom. 1.2 (0.70–2.0). 0.551

Rec. 1.1 (0.33–3.8). 0.864

Allele 1.1 (0.73–1.8). 0.570

GT

29 (27.6)

29 (32.2)

29 (33.0)

TT

6 (6.6)

2 (2.2)

4 (4.5)

MAF; PHWE

0.195; 0.805

0.183; 0.817

0.210; 0.790

EDNRA rs5335 G > C

GG

30 (28.8)

23 (26.1)

25 (28.1)

Studied effect:

Dom. 0.96 (0.55–1.7). 0.893

Rec. 1.1 (0.58–2.0). 0.810

Allele 1.0 (0.71–1.4). 0.958

CG

54 (52.0)

46 (52.3)

45 (50.6)

CC

20 (19.2)

19 (21.6)

19 (21.3)

MAF; PHWE

0.452; 0.452

0.477; 0.477

0.466; 0.466

  1. MAF minor allele frequency, PHWE, a and b indicate significant values after adjusting for multiple testing (the Bonferroni correction: P = 0.036 in both cases) as well as adjusting for covariates: clinical risk factors (model 1) and comorbidities (model 2). Model 1 including GA, BW < 1000 g; Apgar scores at 1 min; a number of RBC transfusions, mechanical ventilation, and surfactant treatment indicated: a: OR = 0.35, 96% CI (0.13–0.95); P = 0.040; and b: OR = 0.25, 96% CI (0.07–0.82); P = 0.023. Model 2 including NEC, BPD, IVH, RDS, and DWMI indicated: a: OR = 0.33, 96% CI (0.14–0.78); P = 0.012; and b: OR = 0.28, 96% CI (0.10–0.78); P = 0.014.
Back to article page